Viralytics Limited (ASX:VLA) has released results showing improved anti-cancer activity from Cavatak when used in combination with immune checkpoint inhibitors.
The immunotherapy company says a preclinical study has shown superior efficacy outcomes in a mouse melanoma study.
The company explains that Cavatak is a proprietary formulation of a common cold virus that has been shown to preferentially infect and attack cancer cells.
CEO Dr Malcolm McColl says these updated results represent a major opportunity for Viralytics to contribute to an exciting new field of cancer treatment.
Viralytics reported a net loss of $5.5 million in the 2014 financial year.
